Lipocine licenses TLANDO franchise to Verity Pharma for $11M upfront, up to $259M milestones plus royalties

Lipocine Inc.

Exclusive US/Canada rights to TLANDO and TLANDO XR; Lipocine receives $11M license fee ($2.5M paid, $5M due Feb 1, 2024).
Eligible for up to $259M in development and sales milestones plus tiered royalties of 12–18% on US/Canada net sales.
Commercialization transitions to Verity Pharma effective Feb 1, 2024; Verity handles all regulatory and marketing obligations.
Lipocine retains all rights outside US/Canada and all non-TRT indications globally.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).

Action: entry
Agreement: license
Counterparty: Gordon Silver Limited and Verity Pharmaceuticals, Inc.
Value: $11 million license fee
Effective: 2024-01-12

Exact text from the filing

On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)

View on SEC.gov

Browse all material agreements →

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-002831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.